COST-EFFECTIVENESS COMPARISON OF BOTULINUM TOXIN TYPE A PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE IN THE TREATMENT OF IDIOPATHIC OVERACTIVE BLADDER WITH URINARY INCONTINENCE AMONG PATIENTS NOT ADEQUATELY MANAGED BY ANTICHOLINERGIC THERAPY IN FRANCE

被引：1
|
作者：
Ruffion, A. [1 ]
Velard, M. [2 ]
Loveman, C. [3 ]
Khalaf, K. [4 ]
Roze, S. [5 ]
Pignata, M. [5 ]
Stanisic, S. [6 ]
Lister, J. [7 ]
机构：
[1] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France
[2] Allergan France SAS, Courbevoie, France
[3] Allergan Holdings Ltd, Marlow, Bucks, England
[4] Allergan Pharmaceut Inc, Irvine, CA USA
[5] HEVA HEOR, Lyon, France
[6] LASER Grp, Milan, Italy
[7] LASER ANALYT, Lorrach, Germany
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.1330
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PUK22
引用
收藏
页码：A470 / A470
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF PANITUMUMAB PLUS BEST SUPPORTIVE CARE (BSC) COMPARED WITH BSC ALONE IN CHEMOREFRACTORY METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) WITH WILD-TYPE (WT) KRAS TUMOR STATUS IN THE NETHERLANDS
    Graham, C. N.
    Borker, R.
    Oppe, M.
    Groot, C. A. Uyl-de
    Barber, B.
    Brogan, A. J.
    Amado, R. G.
    Peeters, M.
    Devercelli, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 134 - 134
  • [32] The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer
    Evans, WK
    LeChevalier, T
    EUROPEAN JOURNAL OF CANCER, 1996, 32A (13) : 2249 - 2255
  • [33] COST-EFFECTIVENESS OF BEST SUPPORTIVE CARE VS. ONABOTULINUMTOXINA, ORAL THERAPIES, PERCUTANEOUS TIBIAL NERVE STIMULATION, AND SACRAL NERVE STIMULATION FOR TREATING OVERACTIVE BLADDER-CLINICAL ASPECTS
    Dmochowski, Roger R.
    Hessami, Sam H.
    Guiltyaev, Dmitry
    Lister, Johanna
    Khalaf, Kristin M.
    Boer, Robert
    NEUROUROLOGY AND URODYNAMICS, 2017, 36 : S67 - S67
  • [34] Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US (vol 40, pg 699, 2022)
    Goswami, Hardik
    Alsumali, Adnan
    Jiang, Yiling
    Schindler, Matthias
    Duke, Elizabeth R.
    Cohen, Joshua
    Briggs, Andrew
    Puenpatom, Amy
    PHARMACOECONOMICS, 2023, 41 (05) : 605 - 605
  • [35] COST-EFFECTIVENESS ANALYSIS OF AVELUMAB PLUS BEST SUPPORTIVE CARE (BSC) VS BSC ALONE AS A FIRST-LINE (1L) MAINTENANCE TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA IN TAIWAN
    Chang, Wc
    Xiao, Y.
    Lin, Ay
    Pj, Su
    Goh, C.
    Wu, E.
    Liu, K.
    Chou, P.
    Kuo, K.
    Palencia, R.
    Chang, J.
    Kearney, M.
    Kapetanakis, V
    Benedict, A.
    VALUE IN HEALTH, 2022, 25 (01) : S58 - S59
  • [36] Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy A Phase 3 Randomized Clinical Trial
    Liu, Guo-Ying
    Li, Wang-Zhong
    Wang, De-Shen
    Liang, Hu
    Lv, Xing
    Ye, Yan-Fang
    Zhao, Chong
    Ke, Liang-Ru
    Lv, Shu-Hui
    Lu, Nian
    Bei, Wei-Xin
    Cai, Zhuo-Chen
    Chen, Xi
    Liang, Chi-Xiong
    Guo, Xiang
    Xia, Wei-Xiong
    Xiang, Yan-Qun
    JAMA ONCOLOGY, 2022, 8 (04) : 553 - 561
  • [37] Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment
    Starling, N.
    Tilden, D.
    White, J.
    Cunningham, D.
    BRITISH JOURNAL OF CANCER, 2007, 96 (02) : 206 - 212
  • [38] Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton's Tyrosine Kinase Inhibitor in Canada
    Ball, Graeme
    Lemieux, Christopher
    Cameron, David
    Seftel, Matthew D.
    CURRENT ONCOLOGY, 2022, 29 (03) : 2021 - 2045
  • [39] Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment
    N Starling
    D Tilden
    J White
    D Cunningham
    British Journal of Cancer, 2007, 96 : 206 - 212
  • [40] Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
    Garcia-Donas, Jesus
    Font, Albert
    Perez-Valderrama, Begona
    Antonio Virizuela, Jose
    Angel Climent, Miquel
    Hernando-Polo, Susana
    Angel Arranz, Jose
    del Mar Llorente, Maria
    Lainez, Nuria
    Carlos Villa-Guzman, Jose
    Mellado, Begona
    Gonzalez del Alba, Aranzazu
    Castellano, Daniel
    Gallardo, Enrique
    Anido, Urbano
    Garcia del Muro, Xavier
    Domenech, Montserrat
    Puente, Javier
    Morales-Barrera, Rafael
    Luis Perez-Gracia, Jose
    Bellmunt, Joaquim
    LANCET ONCOLOGY, 2017, 18 (05): : 672 - 681
12345